NEWTON, Mass.--(BUSINESS WIRE)--PGxHealth, a division of Clinical Data, Inc. (NASDAQ:CLDA) and a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that Karl Rickels, MD, Professor of Psychiatry at the University of Pennsylvania and a prominent clinical investigator who is participating in Vilazodone clinical trials, is presenting a poster at today’s Annual Meeting of the American Psychiatric Association on results from the completed Phase III study of Vilazodone announced in September 2007. The poster is entitled, “Vilazodone: Evidence for Efficacy and Tolerability in the Treatment of Major Depressive Disorder.” This randomized, double-blind, placebo-controlled, ten-site trial enrolled 410 adult patients with major depressive disorder and achieved the primary endpoint of mean change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo (p =.001).
